There are several reasons why a person would require insulin, even if it had not been necessary before.
Some patients may only need to take insulin for a short time to manage the impact of certain conditions such as pregnancy, an illness such as cancer, surgery or if they are taking steroidal medicines. In some instances, the transition to insulin therapy may be permanent as the pancreas is simply unable to produce sufficient insulin.
This usually happens with age, or when a patient has lived with diabetes for many years. Factors such as weight gain and chronic emotional or physical stress can also act as trigger events. The psychological acceptance of insulin therapy is a critical factor to the success of the insulin regimen. Doctors and patients should view insulin initiation and intensification as positive steps toward the ultimate goal – the attainment of as near normal blood glucose levels as possible, in a manner which is individualised to the patient’s needs and lifestyle.
Education and support
In the absence of a well-thought through approach to motivate and support patients throughout the initiation process, many experience difficulty during the transition to insulin therapy. Furthermore, doctors also experience challenges transitioning a patient to insulin therapy such as maintaining compliance, ensuring adequate education takes place and individualising treatment. Patients with concomitant conditions and medications tend to experience greater complexity in initiating insulin, therefore requiring significant and comprehensive education and support. In response, Lilly has created easily understandable and highly impactful healthcare provider and patient support materials which are further supported by diabetes educators. The resources provided by Lilly serve to assist the patient and healthcare provider during the transition to insulin, and dispel the myths and stigma surrounding insulin therapy initiation. Doctors treating patients living with diabetes have access to a comprehensive insulin portfolio, backed with comprehensive support programmes and user-friendly, educational patient materials, all provided by Lilly. It is one of Lilly’s imperatives to help ease the transition to insulin for both the doctor and patient.
Basaglar® is a new basal insulin glargine in Lilly’s insulin portfolio, providing an option for patients with diabetes who need a long-acting solution. As a biosimilar of Insulin Glargine, it is an injectable, prescription medicine designed to be taken at the same time daily to lower blood glucose.* Humalog®, Lilly’s rapid-acting insulin analog, indicated to improve glycemic control in adults and children, provides an option for doctors to intensify treatment with Basalgar if and when required.
Together, they represent an efficacious, well-reimbursed and thoroughly supported basal bolus treatment option for patients living with diabetes. Lilly offers further options through Humalog Mix25 and Humalog Mix50.
Affordability is fundamental
Basaglar and Humalog have little or no co-payments on most medical schemes. Almost all plans under Discovery Health require no additional co-payments. For the uninsured or underinsured, Basaglar comes at a price of up to 30% less than current market alternatives. * Basaglar should not be used to treat diabetic ketoacidosis.